4897-50-1 Usage
Description
4-Piperidinopiperidine is a light yellow to yellow-brown crystalline solid that serves as a versatile reactant in the synthesis of various pharmaceutical compounds. It is a heterocyclic compound with a piperidine ring fused to another piperidine ring, which contributes to its unique chemical properties and potential applications in the pharmaceutical industry.
Uses
4-Piperidinopiperidine is used as a reactant for the synthesis of several pharmaceutical compounds, each with specific applications in different areas of healthcare. 4-Piperidinopiperidine's ability to form a variety of derivatives makes it a valuable building block in the development of new drugs.
Used in Pharmaceutical Industry:
4-Piperidinopiperidine is used as a reactant for the synthesis of:
1. Arylthiadiazole H3 antagonists, which are being investigated for their potential in treating various neurological disorders and conditions related to the histamine H3 receptor.
2. Water-soluble N-mustards, a class of anticancer agents that are designed to target and destroy cancer cells while minimizing damage to healthy cells.
3. Antitubercular drugs, which are essential in the fight against tuberculosis, a global health concern.
4. Vasopressin1b receptor antagonists, which may have potential applications in the treatment of various conditions related to the vasopressin system, such as heart failure and certain types of diabetes.
5. MDR (multidrug resistance) modulators, which are crucial in overcoming resistance to multiple drugs in cancer treatment, thereby improving the effectiveness of chemotherapy.
6. Selective Norepinephrine transporter inhibitors, which may have potential applications in the treatment of conditions such as depression, anxiety, and attention deficit hyperactivity disorder (ADHD).
Check Digit Verification of cas no
The CAS Registry Mumber 4897-50-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,8,9 and 7 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 4897-50:
(6*4)+(5*8)+(4*9)+(3*7)+(2*5)+(1*0)=131
131 % 10 = 1
So 4897-50-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H20N2/c1-2-8-12(9-3-1)10-4-6-11-7-5-10/h10-11H,1-9H2/p+2
4897-50-1Relevant articles and documents
SUBSTITUTED ARYL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF
-
Paragraph 0204; 0206, (2021/11/04)
The present application relates to a substituted aryl compound or a pharmaceutically acceptable salt, a stereoisomer, a polymorph, a solvate, a N-oxide, an isotope-labeled compound, a metabolite or a prodrug thereof, and a preparation method therefor and use thereof, also relates to a pharmaceutical composition containing the compound and a therapeutic use thereof. The compound or a pharmaceutical composition thereof can inhibit the activity of adenosine A2a receptor, and can be used for treating or preventing a disease related to adenosine A2a receptor, especially for treating a tumor.
Cyclic amine derivative and pharmaceutical use thereof
-
Paragraph 0317, (2016/10/09)
The purpose of the present invention is to provide a compound that exerts a strong analgesic action against on pain, in particular, against neuropathic pain and/or fibromyalgia syndrome. The present invention provides a cyclic amine derivative represented by chemical formula, a prodrug thereof or a pharmaceutically acceptable salt thereof.
Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan; CPT-11) toxicity
Hicks, Latorya D.,Hyatt, Janice L.,Stoddard, Shana,Tsurkan, Lyudmila,Edwards, Carol C.,Wadkins, Randy M.,Potter, Philip M.
scheme or table, p. 3742 - 3752 (2010/04/05)
CPT-11 is an antitumor prodrug that is hydrolyzed by carboxylesterases (CE) to yield SN-38, a potent topoisomerase I poison. However, the dose limiting toxicity delays diarrhea that is thought to arise, in part, from activation of the prodrug by a human i